J Rosenstock, R Brazg, PJ Andryuk, K Lu, P Stein - Clinical therapeutics, 2006 - Elsevier This was a 24-week, multicenter, ran domized, double-blind, placebo-controlled, parallel group
study in patients aged ≥18 years (ClinicalTrials. gov NCT00086502). At screening, all patients
began a diet/exercise program that continued throughout the study period. Patients taking ... Cited by 164 - Related articles - All 4 versions
J Rosenstock, MA Baron, R Camisasca, F … - Diabetes, Obesity …, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 111 - Related articles - All 5 versions
- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β cell. Abstract A specific
site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas
leading to closure of the potassium channels and subsequent opening of calcium ... Cited by 87 - Related articles - BL Direct - All 7 versions
- ►ecmaj.ca AYY Cheng, IG Fantus - Canadian Medical Association Journal, 2005 - ecmaj.ca DIABETES MELLITUS IS A CHRONIC DISEASE that is growing in prevalence worldwide. Pharmacologic
therapy is often necessary to achieve optimal glycemic control in the management of
diabetes. Orally administered antihyperglycemic agents (OHAs) can be used either alone ... Cited by 71 - Related articles - All 16 versions
MC Riddle - Endocrinology and metabolism clinics of North America, 2005 - Elsevier We have long known, but now understand more fully that type 2 diabetes is common,
complex, and as treated presently, leads to severe medical consequences. In type 1
diabetes, hyperglycemia is the leading cause of harm. In type 2 diabetes, despite a well- ... Cited by 68 - Related articles - All 3 versions
J Rosenstock, DR Hassman, RD Madder, SA … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Enrolled patients (n = 150) had received treatment with
diet and exercise in the previous 3 months with HbA 1c >7 and ≤12%. Patients were randomized
to receive monotherapy with repaglinide (n = 76) (0.5 mg/meal, maximum dose 4 ... Cited by 63 - Related articles - BL Direct - All 6 versions
P Home - Current Medical Research and Opinion®, 2005 - informahealthcare.com University of Newcastle upon Tyne, Newcastle upon Tyne, UK ... Address for
correspondence: Professor Philip Home, School of Clinical Medical Sciences – Diabetes, The
Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Tel: +44 191 ... Cited by 51 - Related articles - All 6 versions
- ►columbiauniversity.org [PDF] B Kimmel, SE Inzucchi - Clinical Diabetes, 2005 - Am Diabetes Assoc Type 2 diabetes is a multifactorial metabolic disease characterized by abnormalities at multiple
organ sites. These defects include insulin resistance and insulin deficiency. 1,2 The former is
primarily represented by decreased insulin-stimulated glucose uptake in skeletal muscle, ... Cited by 46 - Related articles - All 5 versions
- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, JE … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%). In patients
randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ = −0.8 ± 0.1%, P < 0.0001
vs. placebo). Target HbA 1c (<7.0%) was achieved by 38% of patients treated with ... Cited by 36 - Related articles - BL Direct - All 9 versions
S Del Prato, RJ Heine, L Keilson, C Guitard, SG … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on
pooled data from all completed nateglinide studies (12 randomized, double blind trials and 1
open trial) in patients with type 2 diabetes. A total of 3,702 patients with ≥1 postbaseline ... Cited by 26 - Related articles - BL Direct - All 5 versions
